Nature Medicine10, 475 - 480 (2004)
Published online: 30 April 2004; | doi:10.1038/nm1039
Dendritic cell immunotherapy: mapping the way
Carl G Figdor1, I Jolanda M de Vries1, W Joost Lesterhuis2
& Cornelis J M Melief3
1
Department of Tumor Immunology, Nijmegen Center for Molecular Life Sciences, University Medical Center Nijmegen, PO Box 9101, 6500HB
Nijmegen, The Netherlands.
2
Department of Medical Oncology, Nijmegen Center for Molecular Life Sciences, University Medical Center Nijmegen, PO Box 9101, 6500HB
Nijmegen, The Netherlands.
3
Department of Immunohematology and Blood Transfusion, University Medical Center Leiden, PO Box 9600, 2300RA, Leiden, The Netherlands.
Dendritic cells (DCs) are the professional antigen-presenting cells of the immune system, with the potential to either stimulate or inhibit immune responses. Exploiting the immune-regulatory capacities of dendritic cells holds great promise for the treatment of cancer, autoimmune diseases and the prevention of transplant rejection. Although early clinical trials indicate that DC vaccines can induce immune responses in some cancer patients, careful study design and use of standardized clinical and immunological criteria are needed.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
